Neurocrine Bio (NBIX) - Get Free Report was upgraded to outperform at Oppenheimer. $55 price target. The valuation is more attractive, as the stock is down 22% over the past two months, Oppenheimer said.
Praxair (PX) was upgraded to overweight from neutral at JPMorgan. $125 price target. The company stands to benefit from increased U.S. industrial activity, JPMorgan said.
This article was written by a staff member of TheStreet.